These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17485316)

  • 1. Targeting tumors with hypoxia-activated cytotoxins.
    Ahn GO; Brown M
    Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
    Denny WA; Wilson WR
    Cancer Metastasis Rev; 1993 Jun; 12(2):135-51. PubMed ID: 8375017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
    Weinmann M; Welz S; Bamberg M
    Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):364-74. PubMed ID: 12871083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
    Shibamoto Y; Sugie C; Ito M; Ogino H
    Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour hypoxia: the picture has changed in the 1990s.
    Brown JM; Giaccia AJ
    Int J Radiat Biol; 1994 Jan; 65(1):95-102. PubMed ID: 7905916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of hypoxia selective cytotoxins for cancer treatment: an update.
    Cerecetto H; González M; Lavaggi ML
    Med Chem; 2006 May; 2(3):315-27. PubMed ID: 16948479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
    Patterson LH
    Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.
    Ghattass K; Assah R; El-Sabban M; Gali-Muhtasib H
    Curr Cancer Drug Targets; 2013 Jul; 13(6):670-85. PubMed ID: 23687923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Hunter FW; Wouters BG; Wilson WR
    Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical radiosensitizers for use in radiotherapy.
    Wardman P
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of hypoxia-targeting drugs as new cancer chemotherapeutics.
    Nagasawa H; Uto Y; Kirk KL; Hori H
    Biol Pharm Bull; 2006 Dec; 29(12):2335-42. PubMed ID: 17142959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy approaches to enhance bioreductive drug treatment.
    Cowen RL; Garside EJ; Fitzpatrick B; Papadopoulou MV; Williams KJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S45-56. PubMed ID: 18819998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic applications of metal compounds directed towards hypoxic tissues.
    Gambino D
    Curr Med Chem; 2010; 17(31):3616-31. PubMed ID: 20846115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.
    Greco O; Marples B; Joiner MC; Scott SD
    J Cell Physiol; 2003 Dec; 197(3):312-25. PubMed ID: 14566961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.